Member Info for Brand

Lol the whole gang on one thread

Had a Google. Seems like a good thing.

I know gggg posted this earlier as well. Way over my head - AIM is creating a new segment? A premier League of a small caps? Insight much appreciated.

My buy showing as a sell on here

Topped up 6k shares at 178. Let's go!

Was about 25 minutes by the look of it lol

Would seem your very thorough detail on Pfizer's numbers were a target for some Tony. Makes you wonder who is behind some of the accounts on here.

A very timely reminder that absolutely nothing has changed for sng. Nice one GGG

Some well spoken folks on here very much like to highlight that it would be a DISASTER if the slightest delay were to happen, like these trials aren't moving at light speed relative to pre-covid times. Fair play on oakleaf calling it out, even if he's got it wrong on this occasion and the above posts are genuine.

That whoever was loading up at 191 is now doing the same at 180?

In patients already unwell enough to be in hospital, not just w a positive test.

It's a fair point on Activ, NDN - but would mean w successful results we can compete for m share with the big boys on the early market where they don't have anything (at least to my knowledge) for hospitalised patients.

This is my problem with the Merck and Pfizer pills. Both are the type of thing that you would be very willing to take if you had something really heavy, AIDS, ebola etc - but if you are under 70 and reasonably fit and healthy, are you going to take on the risks involved with both of these drugs right after a positive test?

Or would you look to something that adds a naturally occurring protein to the lungs w little to no potential side effects. I certainly know my preference.

The pills of course are useless for patients showing breathlessness etc, so if you were one of those otherwise fit and healthy people that unfortunately ends up in hospital, it's SNG ftw.

Yes

It's so nice it was worth it twice :)

From the YouTube video of an investors forum widely shared on here, RM put the post successful P3 mcap at 8B based on COPD

Agree that we will see a bit of the potential market size by looking at Merck and Pfizer gains on the back of their press releases.

100% bang on sharedealer.

From the CNN article/Pfizer press release:

"It said 19% of patients given the treatment suffered adverse events, compared to 21% who got placebo, but declined to disclose what those adverse events were.'

I would much rather be best, than first.

It'll bounce, just like after the vaccines were announced

Pfizer press release - see below thread.